Femasys Inc. (NASDAQ: FEMY), a US-based biomedical innovator focused on fertility and non-surgical permanent contraception, has announced an initial order worth approximately $500,000 USD for the commercial rollout of its FemBloc Permanent Birth Control system in France and the Benelux region. The order, placed through the company’s European partner Kebomed, marks another major step in Femasys’ ongoing expansion across key European markets, following its recent entry into Spain.
The move represents continued international momentum for FemBloc, a first-of-its-kind, non-surgical alternative to traditional sterilisation. The product offers women a safer, more convenient, and cost-effective option for permanent birth control without the need for anaesthesia, incisions, or recovery time.
“Our selection of European partners, such as Kebomed, has been deliberate and strategic, ensuring both deep expertise in market access and a shared commitment to advancing women’s healthcare,” said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys Inc. “The initial orders reflect confidence in FemBloc’s potential to transform reproductive health. With these partnerships driving our international expansion, Femasys is well positioned to create lasting impact for patients and long-term value for shareholders.”
Søren Dalmark Kornerup, Chairman of Kebomed Europe AG, said: “We are pleased to partner with Femasys to bring FemBloc to women in France and Benelux. For several years, there has been a void in permanent contraception options, with no new advancements to meet the clear demand from both women and physicians. FemBloc represents a revolutionary breakthrough that the market has been waiting for, and we are thrilled to be at the forefront of introducing this much-needed solution.”
FemBloc uses a patented delivery system to place a proprietary blended polymer into both fallopian tubes, which safely degrades to form natural scar tissue, creating a permanent blockage. The innovation eliminates the surgical risks and recovery periods associated with conventional sterilisation methods.
Femasys secured full regulatory approval for FemBloc in Europe in June 2025, followed by the UK in August and New Zealand in September. The company is continuing to expand through strategic partnerships aimed at making the technology widely available in international markets.
In addition to FemBloc, Femasys’ product portfolio includes FemaSeed® Intratubal Insemination and FemVue®, a diagnostic tool for assessing fallopian tube health. Clinical data shows that FemaSeed is more than twice as effective as traditional intrauterine insemination (IUI), offering a safer and more effective fertility solution.
The company’s ongoing FINALE pivotal trial (NCT05977751) aims to support FemBloc’s U.S. FDA approval. Femasys remains committed to broadening access to innovative reproductive health technologies that improve safety, affordability, and patient outcomes.
